DBV Technologies adds Dr. Hugh Sampson as chief scientific officer
DBV Technologies, a clinical-stage specialty biopharmaceutical company, has appointed Dr. Hugh Sampson chief scientific officer. In partnership with Dr. Dupont, chairman of the company’s scientific advisory board, Sampson will lead DBV’s research team, pursuing new Viaskin applications for the treatment of food allergies, while also supporting the company’s clinical development teams.
Sampson’s appointment becomes effective Nov. 1. Sampson also will continue serving as an advisor to the company, as well as director of the Research Center at the Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York.
Sampson’s research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of food-induced anaphylaxis, the characterization of food-induced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies (recombinant engineered protein, plasmid DNA, peptide, etc.) for treating food allergies. His research has been funded by a number of grants from the NIH and private foundations. He is the Principal Investigator of the NIH-sponsored Consortium of Food Allergy Research (CoFAR). He also is former president of the American Academy of Allergy Asthma and Immunology (AAAAI).